No Data
No Data
Borui Pharmaceutical (688166): Steady revenue growth, R&D efforts continue to increase
The revenue side is growing steadily, and the profit side is under pressure. On April 26, the company announced its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating revenue of 1.18 billion yuan, an increase of 15.9% over the previous year; in fact
Borui Pharmaceutical (688166.SH): Net profit of 640.69,900 yuan in the first quarter decreased by 9.47% year-on-year
On April 27, Ge Longhui Pharmaceutical (688166.SH) released its report for the first quarter of 2024, achieving operating income of 340 million yuan, an increase of 11.54%; net profit attributable to shareholders of listed companies of 640.699 million yuan, a year-on-year decrease of 9.47%; net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses of 64.214,400 yuan, a year-on-year decrease of 7.89%; and basic earnings per share of 0.15 yuan.
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 5.8% Gain Last Week Benefited Both Retail Investors Who Own 34% as Well as Insiders
Key Insights Significant control over BrightGene Bio-Medical Technology by retail investors implies that the general public has more power to influence management and governance-related decisions 51
Borui Pharmaceutical (688166.SH): Selamectin (veterinary) API obtained European CEP certificate
Glonghui, April 19 | Borui Pharmaceutical (688166.SH) announced that the active ingredient selamectin (veterinary) has received a CEP (European Pharmacopeia Suitability Certification) certificate issued by the European Medicines Quality Administration (“EDQM”). Xylamectin (veterinary use) is suitable for the treatment and prevention of parasitic infections in cats/dogs.
Borui Pharmaceutical (688166.SH): Completed repurchases, cumulative repurchases of 0.0860% of shares
Gelonghui, April 18 | Borui Pharmaceutical (688166.SH) announced that as of the disclosure date of this announcement, the company has completed this share repurchase. The company has repurchased 363,461 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.0860% of the company's total share capital. The highest price of the repurchase transaction was 29.94 yuan/share, the lowest price was 25.17 yuan/share, and the total amount of capital paid was RMB 10,005,126.10 (excluding transaction fees such as stamp duty and transaction commissions).
Borui Pharmaceutical (688166.SH): A total of 99,900 shares have been repurchased
Gelonghui, April 1 | Borui Pharmaceutical (688166.SH) announced that as of March 31, 2024, the company had repurchased 99,900 shares through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.0236% of the company's total share capital of 422,466,561 shares. The highest purchase price was 29.94 yuan/share, the lowest price was 28.87 yuan/share, and the total amount of capital paid was RMB 2,941,496.33 (excluding transaction fees such as stamp duty and transaction fees).
No Data